Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have entered into a partnership to develop a systemically delivered RNAi therapeutic, ALN-VSP, for the treatment of liver cancers including hepatocellular carcinoma (HCC). Under the ...
Tags: Alnylam Pharmaceuticals, Ascletis Pharmaceuticals, HCC, ALN-VSP